Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Core Insights - Amphastar Pharmaceuticals reported revenue of $170.53 million for the quarter ended March 2025, reflecting a year-over-year decline of 0.8% [1] - The earnings per share (EPS) for the same period was $0.74, down from $1.04 a year ago, with a surprise of +12.12% compared to the consensus estimate of $0.66 [1] - The reported revenue was a surprise of -0.69% against the Zacks Consensus Estimate of $171.71 million [1] Revenue Breakdown - Primatene MIST generated net revenues of $29.05 million, exceeding the average estimate of $27.64 million, representing a year-over-year increase of +20.2% [4] - Glucagon reported net revenues of $20.84 million, slightly above the estimated $20.24 million, but showed a year-over-year decline of -27% [4] - Lidocaine achieved net revenues of $13.64 million, surpassing the average estimate of $13.15 million, with a year-over-year increase of +6.8% [4] - Epinephrine's net revenues were $18.59 million, above the estimated $18.21 million, but reflected a significant year-over-year decline of -28.8% [4] Stock Performance - Amphastar's shares returned +0.5% over the past month, while the Zacks S&P 500 composite increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]